TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Enhabit, Inc ( (EHAB) ) has issued an update.
Enhabit, Inc. announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, where its executives will discuss the company’s strategic priorities and financial performance. The company has shown significant growth in its home health and hospice segments, with improvements in patient census and financial metrics, indicating a positive trajectory and reduced leverage, which may enhance its market position and stakeholder confidence.
The most recent analyst rating on (EHAB) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Enhabit, Inc stock, see the EHAB Stock Forecast page.
Spark’s Take on EHAB Stock
According to Spark, TipRanks’ AI Analyst, EHAB is a Neutral.
Enhabit, Inc. presents a challenging financial landscape with negative profit margins and declining revenue, which are significant concerns. While there are positive signals from the earnings call in terms of admission and revenue growth alongside cost efficiency improvements, the technical indicators and valuation metrics highlight ongoing struggles. The stock score reflects the need for strategic enhancements and cautious optimism for future performance improvement.
To see Spark’s full report on EHAB stock, click here.
More about Enhabit, Inc
Enhabit, Inc. operates in the healthcare industry, primarily focusing on home health and hospice services. The company aims to provide cost-effective, high-quality care to an aging population, with a strategic focus on growing patient census and optimizing payer mix to stabilize revenue.
Average Trading Volume: 371,958
Technical Sentiment Signal: Buy
Current Market Cap: $546.9M
Learn more about EHAB stock on TipRanks’ Stock Analysis page.

